Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MG in preparation of NLRP3 pathway inhibitor for hyperuricemia nephropathy and/or gouty arthritis

A technology for gouty arthritis and hyperuricemia, applied in the field of biomedicine, can solve problems such as adverse reactions and liver toxicity that limit clinical applications, and achieve a wide range of effects

Pending Publication Date: 2022-02-11
武汉翼博济生生物科技有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Drugs currently on the market for the treatment of hyperuricemia nephropathy (HN) mainly include XOD inhibitors, uricosuric drugs, recombinant uricase supplements, etc., but their adverse reactions and liver toxicity limit their wide clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MG in preparation of NLRP3 pathway inhibitor for hyperuricemia nephropathy and/or gouty arthritis
  • Application of MG in preparation of NLRP3 pathway inhibitor for hyperuricemia nephropathy and/or gouty arthritis
  • Application of MG in preparation of NLRP3 pathway inhibitor for hyperuricemia nephropathy and/or gouty arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] The following is the applicant's further description of the technical solution of the present invention in combination with specific embodiments and accompanying drawings, but the scope of protection claimed by the claims of the present invention is not limited to these embodiments.

[0019] 1 Materials and methods

[0020] 1.1 Experimental animals

[0021] Male C57 mice (No. SCXK(E)2015-0018) were purchased from Hubei Experimental Animal Research Center (Wuhan, China), NLRP3 - / -Mice (NLRP3 knockout mice) were purchased from Shanghai Model Organism Center. Constant temperature environment, regular 12-hour light / dark cycle, and provide standard food and free drinking water. All experimental procedures were performed in accordance with the SCUN Animal Ethics Committee (approval number: 2020-scuec-025), and all procedures involving animals were performed in accordance with the SCUN Animal Experiment Guidelines.

[0022] 1.2 Cell culture and stimulation

[0023] BMDMs (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of methyl gallate (MG) in the preparation of an NLRP3 pathway inhibitor for hyperuricemia nephropathy and / or gouty arthritis. The methyl gallate can specifically inhibit the activation of NLRP3 inflammasomes in BMDMs and PBMCs, and has no influence on the activation of NLRC4 or AIM2 inflammasomes; and the methyl gallate is a wide inhibitor for NLRP3 inflammasome activation, and can inhibit the activation of the NLRP3 inflammasome stimulated by agonists such as LPS / MSU, alum, ATP, nigericin and the like. In addition, the methyl gallate is widely distributed in various edible plants and is wide in source. Therefore, the methyl gallate as an effective component is expected to be developed into the NLRP3 pathway inhibitor for treating hyperuricemia nephropathy and / or gouty arthritis diseases.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of methyl gallate (MG) in the preparation of NLRP3 pathway inhibitors for hyperuricemia nephropathy and / or gouty arthritis. Background technique [0002] Hyperuricemia is a metabolic disease caused by an imbalance in the synthesis or excretion of uric acid in the body. Hyperuricemia refers to the state of blood uric acid level ≥ 420 μmol L-1 in adult males and ≥ 324 μmol L-1 in adult females. Hyperuricemia is closely related to the occurrence of HN and is an important stage in patients with gout. Studies have shown that hyperuricemia is an important risk factor for gout, hypertension, diabetes, cardiovascular complications, metabolic syndrome, and kidney disease. Accumulating evidence indicates that uric acid-induced inflammation is the core mechanism of kidney injury in hyperuricemic rodents, and the NLRP3 pathway may play a central role in it. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/235A61P19/06A61P13/12A61P19/02
CPCA61K31/235A61P19/06A61P13/12A61P19/02
Inventor 陈旅翼刘鹏
Owner 武汉翼博济生生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com